Great Lakes Advisors LLC Sells 233,540 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Great Lakes Advisors LLC lowered its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 49.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 236,552 shares of the company's stock after selling 233,540 shares during the period. Great Lakes Advisors LLC owned about 0.51% of Pacira BioSciences worth $4,457,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of PCRX. Janney Montgomery Scott LLC bought a new stake in shares of Pacira BioSciences in the third quarter worth $793,000. Entropy Technologies LP bought a new stake in Pacira BioSciences during the third quarter valued at about $207,000. Victory Capital Management Inc. grew its holdings in Pacira BioSciences by 39.5% during the third quarter. Victory Capital Management Inc. now owns 122,228 shares of the company's stock valued at $1,840,000 after purchasing an additional 34,589 shares during the period. Impax Asset Management Group plc grew its holdings in Pacira BioSciences by 81.0% during the third quarter. Impax Asset Management Group plc now owns 470,603 shares of the company's stock valued at $7,083,000 after purchasing an additional 210,576 shares during the period. Finally, Empowered Funds LLC bought a new stake in Pacira BioSciences during the third quarter valued at about $3,286,000. Institutional investors own 99.73% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on PCRX shares. Truist Financial raised Pacira BioSciences from a "sell" rating to a "hold" rating and boosted their price target for the company from $8.00 to $25.00 in a report on Thursday, January 30th. Barclays upped their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Needham & Company LLC upped their price objective on Pacira BioSciences from $30.00 to $32.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Finally, HC Wainwright upped their price objective on Pacira BioSciences from $57.00 to $70.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $27.22.

Remove Ads

Pacira BioSciences Trading Up 2.6 %

Shares of PCRX traded up $0.61 during mid-day trading on Wednesday, reaching $24.28. 495,172 shares of the company's stock traded hands, compared to its average volume of 893,418. The stock has a market cap of $1.12 billion, a P/E ratio of -11.96 and a beta of 0.86. The stock's 50-day moving average is $24.15 and its two-hundred day moving average is $19.42. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $31.67. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.